For RA patients, a low score on the patient global assessment of disease activity as measured by a visual analog scale (PGA-VAS) is necessary to confirm remission. However, limited patient health literacy combined with the complexity of the scale may result in discrepancies between the PGA-VAS and provider assessments of disease activity. New research examined the patient perspective on the PGA-VAS and its connections to health literacy and disease state…
Articles by Natasha Yetman
U.S. Government Website for Comparing Doctors Lacks Data
(Reuters Health)—Physician Compare, a U.S. website created to help patients find high-quality doctors, is missing so much information on individual providers that it may not be helpful, a new study suggests. Quality reporting has been a work in progress for almost three decades since a landmark 1999 report from the Institute of Medicine, ‘To Err…
FDA Approves Drug for Lambert-Eaton Myasthenic Syndrome
(Reuters)—Jacobus Pharmaceutical Co Inc on Monday won U.S. approval for the first drug to treat children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder. The drug, Ruzurgi (amifampridine), was approved for use in patients ages 6–17, the according to the U.S. Food and Drug Administration (FDA). Lambert-Eaton myasthenic syndrome (LEMS), which affects about three people…
Summit on Connective Tissue Disease-Associated ILD Fosters Interdisciplinary Dialogue
During an international summit, physicians and researchers discussed the key clinical and research aspects of the complex intersection between connective tissue diseases and interstitial lung disease (ILD), proposing initiatives to raise awareness and conduct research to better serve patients with autoimmune forms of ILD…
Patients Value Convenience of Telemedicine
(Reuters Health)—Patients who have real-time video visits with their primary care providers instead of in-person exams are generally satisfied with the convenience and quality of their checkups, a new study suggests. There’s a lot about these telemedicine visits that can sound appealing: no need to get stuck in traffic on the way to the doctor;…
Scientists May Be Closer to A Blood Test for Chronic Fatigue Syndrome
LONDON (Reuters)—Scientists in the U.S. say they have taken a step toward developing a possible diagnostic test for chronic fatigue syndrome, a condition characterized by exhaustion and other debilitating symptoms. Researchers at Stanford University School of Medicine say a pilot study of 40 people, half of whom were healthy and half of whom had the…
First-Year Medical Residents Spend Little Time on Patient Care
(Reuters Health)—Over a typical 24-hour shift, first year residents training in internal medicine spend just three hours on direct patient care and only 1.8 hours on education, a U.S. study suggests. Most of their time—an average of 15.9 hours out of every 24-hour shift—is consumed instead by “indirect patient care,” primarily involving interactions with medical…
Clusters of Autoimmune Liver Disease Suggest Environmental Trigger
NEW YORK (Reuters Health)—A large population-based study from the U.K. provides more evidence that some autoimmune liver diseases may be triggered by exposure to something in the environment. The study found a significant clustering of cases of primary biliary cholangitis (PBC), autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC) in well-defined regions of north-east England…
U.S. Supreme Court Rejects Allergan Bid to Use Tribe to Shield Drug Patents
WASHINGTON (Reuters)—The U.S. Supreme Court has cast aside pharmaceutical company Allergan Plc.’s unorthodox bid to shield patents from a federal administrative court’s review by transferring them to a Native American tribe. The justices left in place a lower court ruling upholding the authority of a U.S. Patent and Trademark Office tribunal to decide the validity…
FDA Greenlights Osteoporosis Drug for Postmenopausal Women
(Reuters)—The U.S. Food and Drug Administration says it has approved Amgen’s osteoporosis treatment for postmenopausal women who are at high risk of fracture. Evenity (romosozumab-aqqg), developed jointly with Belgium-based UCB SA, helps reduce the risk of fracture by increasing bone mass and mildly inhibiting the break down of bone minerals. Romosozumab-aqqg belongs to a new…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 97
- Next Page »